HYDERABAD: Biological E has entered into an agreement with U.S.-based Vaxinnate Corporation to license its recombinant H1N1 pandemic swine flu vaccine. According to a company release, the vaccine is based on novel ‘Toll-Like Receptor’ (TLR) technology platform which dramatically improves vaccine immunogenicity and efficacy. — Special Correspondent